JCB, Volume 12, Number 4, 2006 Editorial Vol.12 No. 4 (2006) Editorial Neil Henderson   Article Vol.12 No. 4 (2006) Valuing biotechnology companies using the price earnings ratio Jacqueline Loh The biotechnology and life sciences sectors are a source of major source of growth in the economy. However the valuation of companies in the sector is problematic owing Article Vol.12 No. 4 (2006) An overview of trends in multilateral environmental agreements with an impact on biotechnology and research in Asia and the Pacific Frankie Keller The international community has responded to the call for increased management of biotechnology which may harm the environment through participation in multilateral env Article Vol.12 No. 4 (2006) What you give is what you get: Investment in European biotechnology William Bains The European biotechnology industry receives less funding, and less funding per company, than the North American industry, especially at the sensitive early stages of c Article Vol.12 No. 4 (2006) Ticking time bomb: Poorly managed product safety Greg Meline A key paradigm of the pharmaceutical industry has changed. With increased attention towards ensuring the safety of drugs and medical devices, the ability of firms to co Article Vol.12 No. 4 (2006) Cancer remains the dominant disease target for biotech through to 2010 Fleur Pijpers The two leading therapeutic areas for biological products, in terms of current sales and pipeline focus, are oncology and AIID (arthritis, immune and inflammatory disor Legal and Regulatory Updates Vol.12 No. 4 (2006) Legal and regulatory update Gerry Kamstra  Â
